Back to "The previously reported result that GLP-..."
Claim
Strong Support
causal
Analysis v3

GLP-1 receptor agonists, a group of diabetes medications, do not raise the risk of serious heart problems in adults with type 2 diabetes.

33
Pro
0
Against

Mechanism

Synthesis from 1 study

How it works

GLP-1 drugs attach to cells in blood vessels and immune cells, making the vessel lining stronger and lowering harmful inflammation. This prevents damage that could lead to heart attacks or strokes, so the risk of serious heart problems does not increase.

Most probable mechanism

In Simple Terms

GLP-1 receptor agonists bind to receptors on blood vessel walls and immune cells, which makes the lining of blood vessels more stable and reduces the release of inflammatory signals. This prevents damage to the heart and arteries, keeping the risk of serious heart problems from going up.

Causal chain
1

GLP-1 receptor agonists bind to GLP-1 receptors on vascular endothelial cells, enhancing nitric oxide production and improving endothelial barrier integrity

Supported by evidence
which leads to
2

Activation of GLP-1 receptors on macrophages and monocytes suppresses pro-inflammatory cytokine release, including TNF-alpha and IL-6

Supported by evidence
which leads to
3

Reduced endothelial dysfunction and systemic inflammation decrease arterial plaque instability and thrombus formation

Supported by evidence

Evidence from Studies

Supporting (1)

33

Community contributions welcome

33

Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio

Systematic Review With Meta-Analysis
Human
2018 Jul

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Sign up to see full verdict

Source Study

Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio

Score: 33
DOI: 10.1177/1060028018757407

Similar Assertions

Among adults with type 2 diabetes starting injectable treatment, those using GLP-1 receptor agonists had a lower risk of heart attack, stroke, or death over two years compared to those using basal insulin, based on statistical analysis of patient data.

66
0
88%

In adults with type 2 diabetes who start injectable diabetes medication, those using GLP-1 receptor agonists have a lower risk of having a heart attack or being hospitalized for heart failure compared to those using basal insulin, over a period of about two years, regardless of whether they had prior heart disease.

66
0
88%

GLP-1 diabetes drugs help prevent heart attacks and strokes mainly by lowering blood sugar and helping people lose weight—not by lowering blood pressure or bad cholesterol.

48
0
88%

Some diabetes drugs like liraglutide, semaglutide, and dulaglutide may help protect the heart and lower the chance of serious heart problems in people with type 2 diabetes who already have heart disease — and this benefit might not just be because they lower blood sugar.

1
0
86%

In adults who are overweight or obese but do not have diabetes, medications that activate GLP-1 receptors lower the likelihood of heart attacks, strokes, and other serious heart-related events compared to a placebo.

39
0
86%